IBT-B.ST

Infant Bacterial Therapeutics AB (publ) [IBT-B.ST] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

IBT-B.ST Stock Summary

In the News

IBT-B.ST Financial details

Company Rating
-
Market Cap
1.08B
Income
-123.07M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-11.54
Forward P/E
-
PEG
-1.62
P/S
-
P/B
4.06
P/C
-
P/FCF
-14.46
Quick Ratio
9.03
Current Ratio
9.26
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-9.92
EPS next Y
-
EPS next Q
-
EPS this Y
71.55%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
31.6%
-
-
-
-
SMA20
-3.15%
SMA50
61.01%
SMA100
22.4%
Inst Own
-
Inst Trans
-
ROA
-31%
ROE
-38%
ROC
-0.37%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
41.3-106.5
52W High
-46.89%
52W Low
+37.32%
RSI
48.46
Rel Volume
1
Avg Volume
7.03K
Volume
7.01K
Perf Week
-0.18%
Perf Month
-5.54%
Perf Quarter
-
Perf Half Y
5.83%
-
-
-
-
Beta
1.01
-
-
Volatility
0.89%, 1.91%
Prev Close
-1.23%
Price
56.3
Change
-1.92%

Something similar

Top by Market Cap
VTI
VTSAX
M&M.NS
GOOG
ABEC.DE
Same Sector
2189.HK
8769.T
JNJ.DE
TMCI
CTKB
Same Price Range
NMDC.NS
IEF
CPALL-R.BK
GPN
IYH
Similar Market Cap
2488.HK
TV
RSGL.L
RC
FFC

Company Profile

Healthcare Biotechnology
  • Volume Average 7.03K
  • Market Capitalization 1.08B
  • Employee 8
  • CEO Mr. Staffan Stromberg Ph.D.
  • Headquarters Stockholm,SE
  • IPO Date 2016-03-29
  • Website https://www.ibtherapeutics.com

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.